Critical Pharmaceuticals door

Critical Pharmaceuticals Raise £650K

Critical Pharmaceuticals Raise £650K 10/11/2008 09:00

Critical Pharmaceuticals Raise £650K: Investors endorse CriticalMix drug delivery technology and own pipeline potential

Critical Pharmaceuticals, the speciality pharmaceuticals company, today announced  at BioPartnering Europe that it had successfully closed a third round of investment totalling £650,000. Based on the company’s success in developing its unique CriticalMix delivery technology and matching pipeline of candidate drugs, the funding was fully supported by existing shareholders. The company has now raised in excess of £2 million in investment and grants since its formation in 2004 as a spin-out from Nottingham University. It also follows the recent announcement of preclinical results for a sustained release somatropin formulation, which demonstrated considerable advantages over existing once-daily products.

Lisbeth Illum, Chief Executive Officer Critical Pharmaceuticals welcomed the new round: “ The new funds will be used to advance the development of our pipeline of candidate drugs and drug delivery technologies, secure and develop our intellectual property portfolio and invest in our business development capability to secure partnerships with pharmaceutical and biotechnology companies. Already we are attracting growing interest from leading names who can see the advantages of using our drug delivery technology platforms across their drug pipelines. We believe this points to an exciting future for investors and employees. We are also delighted to have attracted new investors in this round as well as the continuing and invaluable support from East Midlands Business Angels (EMBA) and the University of Nottingham who have been with us from the start.”

This confidence was mirrored by one of the lead investors, Jonathan Earl, Investment Director with Catapult Venture Managers: “We believe Critical Pharmaceuticals represents an exciting opportunity. The CriticalMix drug delivery technology not only provides pharmaceutical and biotechnology companies with the opportunity to enhance their own products, but also opens the possibility of Critical developing its own pipeline of differentiated drug products. We look forward to providing support in the company’s growth.”

Existing investor, Nick Wright, Fund Manager of the East Midlands Early Growth Fund at E-Synergy was naturally pleased with the company’s continued success: “For us, Critical Pharmaceuticals is an ideal showcase for the region’s excellence in pharmaceutical services. By combining worldclass research with knowledge of the real needs of the pharmaceutical sector, Critical Pharmaceuticals has made rapid progress. We now welcome the involvement of new investors to help take the company through the next exciting stage of its development.” 

CriticalMix Technology

CriticalMix rig

CriticalMix enables the manufacture of highly active sustained release depot products for bimonthly, monthly or less frequent injection.

Read more

CriticalSorb Technology

nasal device

CriticalSorb enables the non-invasive nasal delivery delivery of high-value biologic products and challenging small molecule drugs.

Read more

Jonathan Earl, Catapult Venture Managers
“We believe Critical Pharmaceuticals represents an exciting opportunity. The CriticalMix drug delivery technology not only provides pharmaceutical and biotechnology companies with the opportunity to enhance their own products, but also opens the possibility of Critical developing its own pipeline of differentiated drug products. We look forward to providing support in the company’s growth.”